First human test for new Alzheimer's pill
NCT ID NCT06285240
Summary
This was an early safety study of a new drug, MK-1167, for Alzheimer's disease. It involved 28 patients who were already taking a standard Alzheimer's medication (donepezil). The main goals were to check for side effects and see how the drug is processed by the body over 24 hours.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel iResearch, LLC ( Site 0003)
Decatur, Georgia, 30030, United States
-
CenExel iResearch, LLC ( Site 0004)
Savannah, Georgia, 31405, United States
-
Velocity Clinical Research, Hallandale Beach ( Site 0001)
Hallandale, Florida, 33009, United States
Conditions
Explore the condition pages connected to this study.